Introduction
Lung cancer histology includes adenocarcinoma (40-60%), squamous cell carcinoma (30-40%), large cell carcinoma (10%) and bronchoalveolar carcinoma (5%) as well as small cell lung cancer (10-20%). Lung adenocarcinoma cells are highly invasive and metastasize early. Approximately 15-30% of lung adenocarcinoma carry oncogenic driver-mutations of either EGFR, KRAS or ALK translocations. EGFR mutations and ALK translocations can be effectively targeted by specific kinase inhibitors. Apart from the identification and targeting of genes specifically mutated in tumors such as EGFR and ALK, the pharmacological targeting of genes governing invasion and metastasis represents a promising approach. Although drugs targeting angiogenesis are active in patients with lung cancer and may have some effects on metastasis, clinical trials with inhibitors targeting proteins directly involved in metastasis, such as matrix metalloproteinase (MMP), failed (Leighl et al., 2005) . This indicates the need for a better understanding of invasion and metastasis mechanisms in order to find novel drug targets.
Among the putative, novel drug targets involved in metastasis are the Src kinase family members. The Src family of non-receptor protein tyrosine kinases contains nine members, including c-Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk and Yrk. Src is part of the focal adhesion kinase complex and mediates normal cell adhesion and migration (Mitra and Schlaepfer, 2006) . The Src signaling pathway is also involved in angiogenesis, cell cycle control and survival. Aberrant expression of activated Src was described in many types of cancer, including lung cancer (Summy and Gallick, 2006) . Several Src inhibitors, including saracatinib and dasatinib, are currently investigated in clinical trials (Rothschild et al., 2010) .
Previously, we identified the inhibitor of DNA binding/differentiation 1 (ID1) as an important downstream mediator of Src (Gautschi et al., 2008) . The ID family of helix-loop-helix proteins comprises four members (ID1-4) that control a wide spectrum of genetic programs (Yokota, 2001) . ID genes are controlled by the Smad-pathway, and can be repressed by transforming growth factor b signaling and by inhibition of c-Myc (Swarbrick et al., 2005) . Expression of ID1 is indispensable for normal embryonic neuronal development and angiogenesis (Lyden et al., 1999) . ID1 is frequently overexpressed in human cancer and associated with aggressive tumor phenotypes (Fong et al., 2004) . Repression of ID1 decreased the growth of early tumors in animal models (Lyden et al., 1999; Lasorella et al., 2001) . We recently showed that ID1 is frequently overexpressed in human lung adenocarcinoma, accompanied by overexpression of Src and MMP9 (Rothschild et al., 2011) . MMP9 belongs to the family of matrix MMPs, mediates cell invasion, and is a known downstream effector of ID1 (Sun et al., 2009) . microRNAs (miRNAs) regulate gene expression at the posttranscriptional level through decreased translation, increased degradation of the target mRNA or both (Valencia-Sanchez et al., 2006; Guo et al., 2010) . The miRNA-target interaction occurs via base pairing of the miRNA seed region (nucleotides 2-7) to the 3 0 -untranslated region (UTR) of the cognate target mRNA (Lewis et al., 2005) . Dysregulation of miRNA expression patterns was found in a variety of human diseases, including a wide spectrum of cancers (Calin and Croce, 2006) . More than 50% of miRNA genes are located within or near chromosomal fragile sites, common breakpoints, or minimal regions of loss-of-heterozygosity or amplification (Calin et al., 2004) . In human cancers, including lung cancer, dysregulated miRNAs can act as oncogenes or tumor suppressors (Croce, 2009) . Several groups showed that miRNA profiling allows to distinguish histological lung cancer subtypes (Lebanony et al., 2009; Bishop et al., 2010) . Furthermore, specific miRNA profiles have been evaluated to predict prognosis and disease recurrence in early-stage lung cancer (Yu et al., 2008; Patnaik et al., 2010) . For example, let-7, which targets KRAS, was one of the first miRNAs found dysregulated in lung cancer with a prognostic role (Takamizawa et al., 2004) . Our current study aimed at identifying miRNAs involved in Src-ID1 signaling to further elucidate this pathway and to better understand potential resistance mechanisms upon Src inhibition. We identified miR-29b as a novel player in this pathway, leading to a better understanding of the biology of invasion and metastasis.
Results

miRNA expression profiling upon Src inhibition in lung cancer cells
To identify miRNAs regulated by c-Src kinase in human lung adenocarcinoma cells, we performed a miRNA array (containing 384 miRNAs) analysis of A549 cells incubated with saracatinib 500 nM for 24 h and compared the data with control-treated A549 cells. A total of 105 miRNAs were downregulated, 53 miRNAs were upregulated and 72 miRNAs remained unchanged with saracatinib (Supplementary Table 1 ). Additional 150 miRNAs were not expressed at detectable levels or remained undetermined. miRNAs upregulated more than twofold were screened for predicted binding sites in the ID1 3 0 -UTR by computed sequence alignment.
miR-29b was the most highly upregulated microRNA with a predicted binding site in the ID1 3 0 -UTR (Supplementary Table 2 and Figure 2a ).
Src inhibition induces miR-29b and reduces ID1 expression
To validate the microRNA profiling results, A549, H460 and H1299 cells were incubated with different concentrations of saracatinib and a second Src inhibitor namely dasatinib. The expression levels of miR-29b were evaluated by quantitative real-time PCR (qRT-PCR). Src inhibition with saracatinib led to a dosedependent increase of miR-29b, up to twofold above basal levels (Figures 1a-c) , and a significant repression of ID1 mRNA levels in all three cell lines (Figures 1d-f) . We repeated the experiments with dasatinib and confirmed an up to 2.5-fold increase of miR-29b (Supplementary Figures 1a-c) and a dose-dependent decrease of ID1 mRNA levels (Supplementary Figures 1d-f). As saracatinib and dasatinib are dual Src/Abl inhibitors, which can also block other members of the Src kinase family, we selectively inhibited c-Src using small hairpin RNA to rule out that inhibition of Abl or other Src family members are responsible for the phenotype seen. The increase in miR-29b expression and the repression of ID1 in A549, H460 and H1299 Src knockdown cells (Figures 1g and h ) were significant and comparable to the increase upon Src inhibitor incubation, clearly supporting the view that saracatinib and dasatinib regulated miR-29b via Src inhibition. A549 cell migration was significantly decreased upon incubation with dasatinib (open wound area 9 vs 78 vs 83%; Po0.001) (Supplementary Figure 1g) . In untreated lung cancer cell lines, basal miR-29b levels were inversely associated with basal ID1 protein levels, independent of KRAS or EGFR mutation status (data not shown).
The ID1 3
0 -UTR is a novel target of miR-29b To demonstrate binding of miR-29b to the ID1 3 0 -UTR, we used a 3 0 -UTR luciferase reporter assay. The alignment of miR-29b with the wild-type ID1 3 0 -UTR and the mutant ID1 3 0 -UTR are illustrated (Figure 2a ). H1299 cells were transfected with the miR-29b expression vector plus a luciferase construct containing either the ID1 3 0 -UTR or a housekeeping gene 3 0 -UTR (peptidylprolyl isomerase A). Only transfection of the wild-type ID1 3 0 -UTR led to a significant decrease (P ¼ 0.01) of the luciferase expression. This suppressive effect of the miR-29b was abolished by mutating the miR-29b site in the ID1 3 0 -UTR (Figure 2b ). These results demonstrate that miR-29b directly inhibits the ID1 3 0 -UTR, thereby reducing ID1 expression.
Expression and prognostic value of miR-29b in patients with lung adenocarcinoma We previously showed that Src and ID1 are significantly co-expressed in human lung adenocarcinoma (Rothschild et al., 2011) . To correlate these data with miR-29b levels, total RNA was extracted from tumors and matched normal lung tissue from all 23 cases in our (Figure 3a) . The miR-29b levels correlated negatively with the previously determined nuclear H-score (McCarty et al., 1985) for ID1 (P ¼ 0.045). Furthermore, there was a nonsignificant negative correlation to the cytoplasmatic H-score for Src. Using the median tumor level as cut-off value, tumor miR-29b expression significantly correlated with event-free (P ¼ 0.003) and overall survival (P ¼ 0.039) (Figures 3b and c) . Thus, miR-29b is a novel prognostic marker in patients with lung adenocarcinoma.
Inhibition of miR-29b leads to increased ID1 levels and cell migration/invasion
To analyze the effects of miR-29b on ID1, MMP9 and invasion in lung cancer cells, we stably transduced A549 and H460 cells using lentiviral vectors containing antisense miR-29b (anti-miR-29b) or scrambled control. As miR-29b is known to target DNA methyltransferase (DNMT)-3A and -3B in lung cancer (Fabbri et al., 2007) , we measured DNMT-3B expression as a control for the effectiveness of miR-29b inhibition. Anti-miR29b led to a two-to threefold increase of DNMT-3B mRNA and protein levels in A549 and H460 cells ( Figure 4b and Supplementary Figure 2a) . Anti-miR29b caused a two-to threefold increase of ID1 mRNA and protein levels (Figures 4a and b) , and increased the levels of MMP9 mRNA in A549 and H460 cells (Supplementary Figure 2b) . In the functional assays, anti-miR-29b significantly induced cell migration (open wound area 12 vs 3%; P ¼ 0.03) and invasion (Po0.001) of A549 cells (Figures 4c and d ).
Ectopic expression of miR-29b reduces lung cancer cell migration and invasion To further investigate the role of miR-29b, we examined next the effect of ectopic expression of this miRNA on 
Repression of miR-29b by c-Myc in lung cancer cells
As previously shown by others, saracatinib decreased the binding of b-Catenin to the promoter of Myc in prostate cells (Chang et al., 2008b) , and miR-29b was repressed by Myc in leukemia cells . We therefore studied the effect of saracatinib on the miR-29b inhibition and ectopic ID1 expression modulate Src kinase inhibitor activity To investigate whether ID1 and miR-29b can modulate the activity of Src kinase inhibitors in vitro, we performed migration and invasion assays using saracatinib, A549 cells transduced with anti-miR-29b or a scrambled vector. Whereas saracatinib reduced migration and invasion of control cells, this effect was significantly diminished in anti-miR-29b transduced cells (Figures 7a and b) . This effect seemed to be mainly modulated by ID1 expression levels, which are significantly higher in miR-29b-inhibited cells, and did not decrease upon Src inhibition (Figure 7c ). These results were confirmed with dasatinib (Supplementary Figure  1h) . Consistently, ID1 transduction of A549 cells significantly diminished the activity of saracatinib (Figures 7d and e) .
Discussion
An increasing number of miRNAs is implicated in cancer by altering fundamental cellular processes (Caldas and Brenton, 2005) . In the present study, using the Src-specific small molecule inhibitors saracatinib and dasatinib, we identified miR-29b as an important mediator of the Src-ID1 pathway, controlling lung cancer cell invasion. Members of the miRNA-29 family (miR-29a, miR-29b and miR-29c) are known to be highly expressed in normal tissues and downregulated in different types of cancer, including neuroblastoma, sarcoma, glioma, high-risk chronic lymphatic leukemia, invasive breast cancer, cholangiocarcinoma and lung cancer (Calin et microRNA-29b in lung cancer SI Rothschild et al et al., 2006; Mott et al., 2007; Wu et al., 2009; Xu et al., 2009) . The three miR-29 isoforms are arranged in two clusters: miR-29b1/miR-29a located on chromosome 7q32 and miR-29b2/miR-29c located on chromosome 1q32. miR-29a has been shown to reduce invasiveness and proliferation of human carcinoma cell lines (Muniyappa et al., 2009) . miR-29b was previously correlated with good prognosis in patients with acute myeloid leukemia, and has a tumor suppressor function in leukemic blasts by targeting apoptosis, cell cycle and proliferation pathways (Garzon et al., 2008) . Consistently, miR-29b regulates Mcl-1 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in cholangiocarcinoma cells, and controls Tcl-1 in chronic lymphatic leukemia cells (Pekarsky et al., 2006; Mott et al., 2007) . The miR-29 family members also target DNMT3A and DNMT3B, and can thereby restore patterns of DNA methylation and expression of silenced tumor suppressor genes (Fabbri et al., 2007) . Although we did not exclude the possibility that inhibition of Src or manipulation of miR-29b changed methylation of the ID1 promoter in our study, we demonstrated that miR-29b binds to the ID1 3 0 -UTR, and that this direct interaction has functional implications. We showed that inhibition of endogenous miR-29b by stable transduction of a lentiviral vector containing an antisense miR-29b in human lung cancer cells caused an increase in ID1 and MMP9, and enhanced matrigel invasion. In contrast, stable overexpression of miR-29b caused a decrease in ID1 and MMP9 levels (data not shown) and significantly impaired the invasion. Upon ectopic expression of ID1 in these cells, the migratory potential was rescued. Together, these results suggest that by direct interaction with ID1 and regulation of MMP9, which is a known target of ID1, miR-29b has an important role in the regulation of lung cancer cell migration and invasion.
In vitro, the Myc proto-oncogene is able to suppress the expression of several miRNAs, including the members of the miR-29 family . These cells were used for migration assay. Light microscopy images were performed 18 h after scratching of the monolayer (g). The transfection efficiency for ID1 in A549-miR-29b was assessed by western blotting for ID1 (h).
microRNA-29b in lung cancer SI Rothschild et al miR-29b by hedgehog signaling and NF-kB activation was also reported (Mott et al., 2010) . Our data support the negative regulation of miR-29b and ID1 by c-Myc because forced expression of c-Myc in lung cancer cells suppressed miR-29b levels and induced the expression of ID1. Furthermore, we could show direct recruitment of c-Myc to the miR-29b promoter in lung cancer cells. 
A549 anti miR-29b
Figure 7 miR-29b and ID1 modulate the activity of Src kinase inhibitors. (a) Migration assay with A549 cells transduced with a control vector (control), or a lentiviral vector containing antisense miR-29b (anti-miR-29b). Cells were incubated with saracatinib in DSMO or with DMSO alone. Light microscopy images were performed immediately after scratching of the monolayer (0 h), and 24 h later. (b) Invasion assay with A549 cells transduced with a control vector, or a lentiviral vector containing anti-miR-29b. Cells were incubated in matrigel chambers with saracatinib and DSMO or with DMSO alone. After 24 h, cells at the bottom of the insert were stained and counted. Bars ± s.d. show the median of three independent experiments, statistical analysis by Mann-Whitney U test (Po0.001). (c) qRT-PCR for ID1 in A549 control cells and A549 cells stably transduced with anti-miR-29b. Results were normalized to 18sRNA and are shown as n-fold decrease relative to the level in the control cells. Differences in expression levels were analyzed by Mann-Whitney U test, *Po0.05; **Po0.001. (d) Migration assay with A549 cells transduced with a control vector (control), or a retroviral vector containing ID1. Cells were incubated with saracatinib in DSMO or with DMSO alone. Light microscopy images were taken immediately after scratching of the monolayer (0 h), and 24 h later. (e) Invasion assay with A549 cells transduced with a control vector, or a retroviral vector containing ID1. Cells were incubated in matrigel chambers with saracatinib and DSMO or with DMSO alone. After 24 h, cells at the bottom of the insert were stained and counted. Bars ± s.d. show the median of three independent experiments, statistical analysis by Mann-Whitney U test (Po0.001).
microRNA-29b in lung cancer SI Rothschild et al indicated by our microRNA-array data, additional miRNAs may also contribute to the regulation of ID1 by Src, and experiments are ongoing to determine their role in lung cancer pathogenesis. In formalin-fixed and paraffin-embedded lung adenocarcinoma samples, miR-29b was significantly downregulated compared with the neighboring alveolar lung tissue. Tumor miR-29b levels inversely correlated with tumor ID1 protein measured by semiquantitative immunohistochemistry, but not with ID1 mRNA measured by qRT-PCR (data not shown). Discordant mRNA and protein levels in tumors have also been reported for other genes, and may be caused by different mechanisms of action of miRNAs. miRNAs regulate gene expression at the posttranscriptional level through decreased translation, increased degradation of the target mRNA or both (Valencia-Sanchez et al., 2006) . We hypothesize that in vivo miR-29b regulates ID1 mostly by decreased translation, explaining the difference in correlation of mRNA and protein levels. Further analyses are needed to confirm the inverse relationship between miR-29b and ID1 expression in vivo. Although the sample number in our study was rather small, low miR-29b tumor levels significantly correlated with poor event-free and overall survival, whereas high miR-29b tumor levels were associated with favorable outcome. A recent study found no prognostic role for miR-29b in patients treated with adjuvant chemotherapy after complete resection of lung cancer (Voortman et al., 2010) . However, patients had different histological subtypes, and the study used a different control gene for standardization and a different cut-off value. Therefore, additional studies are needed to confirm a potential prognostic value of miR-29b in patients with lung adenocarcinoma.
ID1 and miR-29b expression levels potentially have a predictive role for Src inhibitors in lung adenocarcinoma. Positive and negative regulation of ID1 transcription by bone morphogenetic protein (BMP) and transforming growth factor via the Smad pathway is well established (Langenfeld et al., 2003) . Recently, a crosstalk between Src kinase and the Smad-ID1 pathway was described that led to a new way to target ID1 using Src inhibitors, such as saracatinib or dasatinib (Gautschi et al., 2008) . These compounds are currently tested in patients with lung cancer, because Src is frequently expressed and activated in lung cancer (Rothschild et al., 2010) .
Our present study showed that constitutive overexpression of ID1 in lung cancer cells diminished the effect of saracatinib and dasatinib on migration and invasion in vitro. The same was observed when cells were transduced with a vector containing an antisense miR29b construct. To our knowledge, these results indicate for the first time that ID1 and miR-29b modulate the sensitivity of lung cancer cells to pharmacological Src kinase inhibitors. Available data from clinical trials with saracatinib and dasatinib indicate that these drugs have modest activity when used as single agents in unselected patients with lung cancer . We propose that ID1 and miR-29b may have a potential predictive role for the activity of Src inhibitors in lung cancer, which should be explored by translational studies.
Materials and methods
Cell lines and reagents
The following cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA): A549, H460 and H1299. H820, HCC827 and HCC4011 were provided by Dr. John Minna (UT Southwestern, Medical Center, Dallas, TX, USA). Mycoplasma testing and morphological analysis of the cells was done before starting the experiments. Cells were grown in Dulbecco's Modified Eagle Medium (Sigma-Aldrich, Buchs, Switzerland) or in Roswell Park Memorial Institute medium-1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum and antibiotic-antimycotic solution (penicillin 100 U/ml, streptomycin sulfate 100 mg/ml and amphotericin B 0.25 mg/ml; Sigma-Aldrich) at 37 1C in a 5% CO 2 -humified atmosphere. Saracatinib (AstraZeneca Pharmaceuticals, Macclesfield, UK) and dasatinib (LC Laboratories, Woburn, MA, USA) were solubilized in dimethyl sulfoxide to obtain a 10-mmol/l stock solution, which was stored at À20 1C and diluted in Dulbecco's modified Eagle medium or Roswell Park Memorial Institute medium-1640 for each experiment. 10058-F4 (5-[(4-ethylphenyl)methylene]-2-thioxo-4-thiazolidinone) (Sigma-Aldrich) was dissolved in dimethyl sulfoxide and cells were treated as indicated.
Reverse transcription-PCR Total RNA was extracted using the miRNeasy mini kit and the RNase-free DNase Set to minimize risk of contamination with genomic DNA, according to the manufacturer's protocol (Qiagen, Hombrechtikon, Switzerland). Total RNA of 1-2.5 mg was reverse transcribed using random primers and M-MLV Reverse Transcriptase (Promega AG, Du¨bendorf, Switzerland). For miRNA analysis, 1 mg RNA was reverse transcribed using miScript Reverse Transcription Kit (Qiagen). microRNA-29b in lung cancer SI Rothschild et al 23 cases with a pathological diagnosis of lung adenocarcinoma and available tissue were included in the present study. All patients gave informed consent for retention and analysis of their tissue for research purposes. The Ethical Committee of the Canton Bern approved the tissue banking and the current project. In addition to tissue blocks for conventional histological diagnosis, formalin-fixed and paraffin-embedded tissue blocks of a tumor tissue bank from six randomly chosen sites within the surgical specimen taken for analysis of nonmalignant tissue were available. RNA extraction from formalin-fixed and paraffin-embedded was performed as previously described (Oberli et al., 2008) using the miRNeasy mini Kit (Qiagen).
Clinical samples
miRNA array Total RNA extraction from control or saracatinib (500 nM, 24 h)-treated A549 cells was done using the miRNeasy mini Kit (Qiagen). Optimal miRNA quality was ensured using an Agilent 2100 Bioanalyzer (Agilent Technologies, Basel, Switzerland). To assess miRNA expression profiles, we used the TaqMan Array Human MicroRNA Cards v2.0 (Applied Biosystems, Rotkreuz, Switzerland) according to the manufacturer's protocol. This set enables accurate quantification of 384 miRNAs including four control assays, three candidate endogenous control assays and one negative control assay. Expression data were normalized to the expression of the included control miRNAs. miRNAs with more than twofold changes in expression levels upon incubation with saracatinib compared with nontreated cells were analyzed for binding sites in the ID1 3 0 -UTR.
MicroRNA target prediction
We used the following target prediction software to identify miRNAs that potentially bind ID1: Pictar (Krek et al., 2005) Luciferase reporter assays H1299 cells were seeded in 96-well plates (50 000 cells per well). After 24 h, cells were transfected either with luciferase reporter plasmids containing a housekeeping gene 3 0 -UTR (peptidylprolyl isomerase A), ID1 3 0 -UTR (SwitchGear Genomics, Menlo Park CA, USA) or mutated ID1 3 0 -UTR. The ID1 3 0 -UTR with a mutated miR-29b-binding site was generated using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla CA, USA) and the following oligonucleotides: f5 0 -AAAGCAGACATTTTAAAAAATGGTCACG TTTGATATCTCTCAGATTTCTGAGGAAATTGCTTTGT ATTG-3 0 and 5 0 -CAATACAAAGCAATTTCCTCAGAA ATCTGAGAGATATCAAACGTGACCATTTTTTAAAATG TCTGCTTT-3 0 . The site-specific mutations were confirmed by DNA sequencing. These constructs were co-transfected with MISSION Human miRNA Mimics (Sigma-Aldrich) using Lipofectamine 2000 (Invitrogen, Basel, Switzerland) . Cells were lysed 24 h after transfection and the activities of Firefly (Photinus pyralis) and Renilla (Renilla reniformis) luciferases were determined with a dual-luciferase assay system (Promega). Values, normalized to housekeeping gene 3 0 -UTR-transfected cells and relative to cells transfected with nontargeting control miRNA, are the means of three independent experiments.
qRT-PCR qRT-PCR was performed using iQ Sybr Green Supermix (BioRad Laboratories AG, Reinach, Switzerland). Primer sequences for ID1 and 18 s RNA have been published previously (Gautschi et al., 2008) . Sequences for DNMT-3B and MMP9 were: 5 0 -GAAGGGAGACACCAGGCATC-3 0 (forward), 5 0 -CGTAGGGGGTACTGCTGCTC-3 0 (reverse), 5 0 -CGGCTT GCCCTGGTGCAGT-3 0 (forward) and 5 0 -CGTCCTGGGTG TAGAGTCTCTCG-3 0 (reverse). miR-29b expression was assessed using the miScript SYBR Green PCR kit and primer assay hsa-miR-29b (Qiagen). All measurements were performed in duplicates, and the arithmetic mean of the comparative threshold cycle (Ct) values was used for calculations. Target gene mean Ct values were normalized to the respective housekeeping gene (18sRNA for mRNAs or SNORA-73A for miRNAs, respectively), mean Ct values (internal reference gene, DCt) and then to the experimental control (DDCt). Obtained values were exponentiated (2 ÀDDCt ) to be expressed as n-fold changes in regulation compared with the experimental control (Livak and Schmittgen, 2001) . Standard dilutions and melting curve analyses were performed to confirm accuracy. For normalizing miRNAs, several potential housekeeping miRNAs have been evaluated for stability in expression levels, and SNORA-73A was found to be the most stable miRNA in our cell lines upon Src inhibition. All qRT-PCR reactions were carried out on a 7900HT Fast Real-Time PCR system (Applied Biosystems).
